中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03681 中国抗体-B

休市中 03-13 16:08:19

1.720

-0.120

-6.52%

最高1.810	最低1.680	成交量585.97万
今开1.790	昨收1.840	日振幅7.07%
总市值23.86亿	流通市值23.86亿	总股本13.87亿
成交额1,019万	换手率0.42%	流通股本13.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03681","market":"HK","secType":"STK","nameCN":"中国抗体-B","latestPrice":1.72,"timestamp":1773389299125,"preClose":1.84,"halted":0,"volume":5859700,"delay":0,"changeRate":-0.06521739130434788,"floatShares":1387000000,"shares":1387000000,"eps":-0.17244,"marketStatus":"休市中","change":-0.12,"latestTime":"03-13 16:08:19","open":1.79,"high":1.81,"low":1.68,"amount":10185276,"amplitude":0.070652,"askPrice":1.73,"askSize":46800,"bidPrice":1.72,"bidSize":83100,"shortable":0,"etf":0,"ttmEps":-0.114,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":7,"adr":0,"listingDate":1573488000000,"exchange":"SEHK","adjPreClose":1.84,"openAndCloseTimeList":[[1773365400000,1773374400000],[1773378000000,1773388800000]],"volumeRatio":2.4632179848408957,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03681/wiki","defaultTab":"wiki","newsList":[{"id":"2618135630","title":"中国抗体-B(03681)附属终止租赁协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618135630?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:44","pubTimestamp":1773312249,"startTime":"0","endTime":"0","summary":"经考虑本公司优化资源配置及提升营运灵活性的策略，订约方已就提前终止租赁协议展开商讨。经长时间磋商后，订约方均同意终止租赁协议。董事会认为，终止协议对本公司向轻资产制造模式过渡而言属于合理且务实。董事会认为，终止协议不会对本集团的财务状况或营运构成任何重大不利影响，并符合本公司及其股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2618053927","title":"中国抗体-B03月11日遭主力抛售57.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618053927","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618053927?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216937,"startTime":"0","endTime":"0","summary":"03月11日, 中国抗体-B股价跌1.55%，报收1.90元，成交金额259.8万元，换手率0.10%，振幅5.18%，量比0.41。中国抗体-B今日主力资金净流出57.0万元，上一交易日主力净流出121.4万元。该股近5个交易日下跌2.56%，主力资金累计净流入88.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2221.2万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161802a6b78793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161802a6b78793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2618687459","title":"中国抗体-B拟3月23日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618687459","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618687459?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:38","pubTimestamp":1773142693,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨中国抗体-B(03681.HK)公告，谨定于2026年3月23日(星期一)举行董事会会议，以考虑及通过集团截至2025年12月31日止年度全年业绩及其发布，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310193825a6b55ef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310193825a6b55ef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"1125106901","title":"中国抗体-B（03681）2月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125106901","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125106901?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:36","pubTimestamp":1772699782,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年3月5日发布了截至2026年2月28日的股份变动月报。公告显示，公司香港联交所股票代码为03681，目前已发行普通股总数为1,386,638,336股，与上月底持平，报告期内未有新增发行、购回或库藏股变动。\n报告称，公司现行的股份期权计划截至报告期末仍有69,009,462份期权未行使，数量与上月底保持一致。本月内并无期权行使或失效行为，亦未出现新增发行或从库藏股份转让的情况。\n截至本月末，公司股本保持稳定，亦确认符合香港联交所的相关上市规则及法律法规要求。本次公告由执行董事、主席兼首席执行官梁瑞安签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"gpt_icon":0},{"id":"2617265045","title":"中国抗体-B03月05日主力净流入249.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2617265045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617265045?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:16","pubTimestamp":1772698565,"startTime":"0","endTime":"0","summary":"03月05日, 中国抗体-B股价涨1.54%，报收1.98元，成交金额929.9万元，换手率0.33%，振幅7.18%，量比0.59。中国抗体-B今日主力资金净流入249.0万元，上一交易日主力净流出47.1万元。该股近5个交易日下跌7.04%，主力资金累计净流出96.0万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2914.5万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162140a44eea3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162140a44eea3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"2617052650","title":"中国抗体-B盘中异动 早盘急速拉升5.13%报2.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617052650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617052650?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:17","pubTimestamp":1772677031,"startTime":"0","endTime":"0","summary":"2026年03月05日早盘10时17分，中国抗体-B股票出现异动，股价大幅上涨5.13%。截至发稿，该股报2.050港元/股，成交量300.27万股，换手率0.22%，振幅3.08%。资金方面，该股资金流入442.203万港元，流出157.545万港元。中国抗体-B股票所在的生物技术行业中，整体涨幅为2.57%。中国抗体-B公司简介：中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的中国香港生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603051017119543119f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603051017119543119f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"gpt_icon":0},{"id":"2614852880","title":"中国抗体-B02月27日遭主力抛售231.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852880?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:16","pubTimestamp":1772180162,"startTime":"0","endTime":"0","summary":"02月27日, 中国抗体-B股价跌5.16%，报收2.02元，成交金额1458.0万元，换手率0.51%，振幅6.57%，量比0.99。中国抗体-B今日主力资金净流出231.5万元，上一交易日主力净流出32.7万元。该股近5个交易日上涨1.00%，主力资金累计净流出179.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2653.4万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227162132a4cf0004&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227162132a4cf0004&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","03681"],"gpt_icon":0},{"id":"2614189017","title":"中国抗体-BSM17新适应症获批临床，研发加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2614189017","media":"国元证券(香港)","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614189017?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:14","pubTimestamp":1772093694,"startTime":"0","endTime":"0","summary":"针对炎症性肠病，公司计划利用已有I期数据快速推进至II期临床。根据预测，到2032年，AD药物市场规模将达352亿美元，而IBD患者人数超过680万，现有药物缓解率仅10%-20%，存在重大未满足需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2614277992","title":"港股异动 | 中国抗体-B(03681)午前涨超5% 预计最早于二季度启动针对SM17 AD的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2614277992","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614277992?lang=zh_cn&edition=full","pubTime":"2026-02-25 11:49","pubTimestamp":1771991346,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国抗体-B午前涨超5%，截至发稿，涨4.48%，报2.1港元，成交额952.99万港元。消息面上，中国抗体-B发布公告，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。有关研究数据将用作支持IBD适应症的进展直接推进II期临床开发。公司预计最早于本年第二季度启动针对AD的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AD","03681","VT","VXUS","BK4588","BK4132","BK4585","BK1574","BK1161"],"gpt_icon":0},{"id":"2613717630","title":"中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613717630?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:01","pubTimestamp":1771941713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布，于2026年2月24日，公司同类首创治疗产品SM17用于治疗炎症性肠病患者的新药临床试验申请已获中国国家药品监督管理局批准。公司已完成针对使用SM17皮下注射剂型的健康志愿者I期桥接实验的随访。该机制使SM17成为UC有前景的治疗候选药物，其中已证实IL-25发挥促炎作用。公司进一步认为，靶向2型炎性通路上游调控因子的治疗策略可支持SM17成为用于治疗AD及IBD的具差异化、安全性更佳且有效的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","IND","IBD","03681"],"gpt_icon":0},{"id":"2612250475","title":"中国抗体-B02月20日获主力加仓57.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612250475","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612250475?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:15","pubTimestamp":1771575326,"startTime":"0","endTime":"0","summary":"02月20日, 中国抗体-B股价涨2.56%，报收2.00元，成交金额1634.6万元，换手率0.58%，振幅5.64%，量比1.13。中国抗体-B今日主力资金净流入57.2万元，连续4日净流入，上一交易日主力净流入977.7万元。该股近5个交易日上涨18.34%，主力资金累计净流入1766.9万元；近20日主力资金累计净流入2756.6万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161622a4b5db49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220161622a4b5db49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2612252540","title":"港股异动 | 中国抗体-B(03681)再涨超5% SM17临床前研究凸显治疗CRSwNP和IPF强大潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2612252540","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612252540?lang=zh_cn&edition=full","pubTime":"2026-02-20 15:14","pubTimestamp":1771571647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国抗体-B再涨超5%，截至发稿，涨4.62%，报2.04港元，成交额1336.18万港元。消息面上，中国抗体宣布，其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开放研究》上发表。中国抗体董事长、执行董事兼首席执行官梁瑞安称，非常高兴公司在《欧洲呼吸杂志子刊-开放研究》上发表了关于SM17的临床前研究，突显了其治疗CRSwNP和IPF的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","03681","VT","BK4585","VXUS","BK4588","BK1161"],"gpt_icon":0},{"id":"2611918552","title":"中国抗体-B盘中异动 急速上涨5.03%报1.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611918552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611918552?lang=zh_cn&edition=full","pubTime":"2026-02-13 10:11","pubTimestamp":1770948699,"startTime":"0","endTime":"0","summary":"2026年02月13日早盘10时11分，中国抗体-B股票出现异动，股价快速拉升5.03%。截至发稿，该股报1.880港元/股，成交量368.19万股，换手率0.27%，振幅6.15%。资金方面，该股资金流入647.98万港元，流出17.8515万港元。中国抗体-B股票所在的生物技术行业中，整体跌幅为1.13%。其相关个股中，中国抗体-B、科笛-B、维升药业-B涨幅较大，振幅较大的相关个股有北海康成-B、荃信生物-B、中国抗体-B，振幅分别为9.76%、7.37%、6.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021310113997a60562&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021310113997a60562&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","03681"],"gpt_icon":0},{"id":"2610516279","title":"每日卖空追踪 | 中国抗体-B 02月11日卖空量成交14.13万股，卖空比例为2.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610516279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610516279?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798637,"startTime":"0","endTime":"0","summary":"中国抗体-B北京时间02月11日，涨2.96%，卖空量成交14.13万股，较上一交易日减少38.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163512a6ee1f28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163512a6ee1f28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2610918888","title":"中国抗体-B02月11日主力净流入271.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2610918888","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610918888?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:15","pubTimestamp":1770797718,"startTime":"0","endTime":"0","summary":"02月11日, 中国抗体-B股价涨2.96%，报收1.74元，成交金额1132.4万元，换手率0.48%，振幅5.33%，量比0.81。中国抗体-B今日主力资金净流入271.3万元，上一交易日主力净流出7.3万元。该股近5个交易日上涨21.68%，主力资金累计净流入1469.9万元；近20日主力资金累计净流入888.8万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161556a6ee0866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211161556a6ee0866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2609559985","title":"每日卖空追踪 | 中国抗体-B 02月06日卖空量成交60.15万股，卖空比例为4.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609559985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609559985?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366636,"startTime":"0","endTime":"0","summary":"中国抗体-B北京时间02月06日，涨6.37%，卖空量成交60.15万股，较上一交易日减少1.86%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163612a6dac4d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163612a6dac4d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","03681"],"gpt_icon":0},{"id":"2609599814","title":"中国抗体-B02月06日获主力加仓539.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609599814","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609599814?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:15","pubTimestamp":1770365757,"startTime":"0","endTime":"0","summary":"02月06日, 中国抗体-B股价涨6.37%，报收1.67元，成交金额2124.9万元，换手率0.92%，振幅10.83%，量比2.98。中国抗体-B今日主力资金净流入539.1万元，上一交易日主力净流入546.6万元。该股近5个交易日上涨22.79%，主力资金累计净流入1071.6万元；近20日主力资金累计净流入128.5万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206162140a6dab28b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206162140a6dab28b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"1178602596","title":"中国抗体（03681）2026年1月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1178602596","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178602596?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:37","pubTimestamp":1770194232,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年2月4日发布截至2026年1月31日的股份变动月报表。公告显示，公司在报告期内未有新增发行、购回或注销股份，股本保持稳定。根据公告，公司普通股于期末的已发行股份总数维持在1,386,638,336股，且无任何库存股份变动。报告期内亦无因股份期权行使而发行新股的情况。公司确认当前公众持股量已满足香港联交所的相关规定。期权及激励方面，截至1月31日，购股权计划总数为69,009,462份，期内无新增或失效变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"gpt_icon":0},{"id":"2608500993","title":"每日卖空追踪 | 中国抗体-B 02月04日卖空量成交4.53万股，卖空比例为1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608500993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608500993?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:30","pubTimestamp":1770193834,"startTime":"0","endTime":"0","summary":"中国抗体-B北京时间02月04日，涨2.14%，卖空量成交4.53万股，较上一交易日减少81.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163747a6d205b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163747a6d205b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"2608350096","title":"中国抗体-B盘中异动 急速拉升5.00%报1.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608350096","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608350096?lang=zh_cn&edition=full","pubTime":"2026-02-04 14:10","pubTimestamp":1770185435,"startTime":"0","endTime":"0","summary":"2026年02月04日下午盘14时10分，中国抗体-B股票出现波动，股价大幅上涨5.00%。截至发稿，该股报1.470港元/股，成交量149.55万股，换手率0.11%，振幅7.86%。资金方面，该股资金流入111.95万港元，流出97.2393万港元。中国抗体-B股票所在的生物技术行业中，整体涨幅为0.86%。中国抗体-B公司简介：中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的中国香港生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020414103697a4cacd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020414103697a4cacd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinomab.com","stockEarnings":[{"period":"1week","weight":-0.1179},{"period":"1month","weight":-0.0115},{"period":"3month","weight":0.1467},{"period":"6month","weight":-0.0337},{"period":"1year","weight":0.4701},{"period":"ytd","weight":0.2836}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.0854},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司。该公司主要研制以单克隆抗体为基础的生物制剂和新化学实体, 主要产品包括治疗类风湿关节炎的潜在单抗药物SM03。 该公司研发药物还包括有治疗特应性皮炎，哮喘，特发性肺纤维化及其他免疫性疾病潜力的SM17以及针对系统性红斑狼疮, 天疱疮，多发性硬化症及视神经脊髓炎普系疾病的SN1011 。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.001496},{"month":2,"riseRate":0.428571,"avgChangeRate":0.047286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.040334},{"month":4,"riseRate":0.833333,"avgChangeRate":0.072617},{"month":5,"riseRate":0.166667,"avgChangeRate":0.000649},{"month":6,"riseRate":0.333333,"avgChangeRate":0.050967},{"month":7,"riseRate":0.333333,"avgChangeRate":0.028393},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.139986},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048263},{"month":10,"riseRate":0,"avgChangeRate":-0.071195},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.003752},{"month":12,"riseRate":0.428571,"avgChangeRate":0.081979}],"exchange":"SEHK","name":"中国抗体-B","nameEN":"SINOMAB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国抗体-B,03681,中国抗体-B股票,中国抗体-B股票老虎,中国抗体-B股票老虎国际,中国抗体-B行情,中国抗体-B股票行情,中国抗体-B股价,中国抗体-B股市,中国抗体-B股票价格,中国抗体-B股票交易,中国抗体-B股票购买,中国抗体-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}